Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: A new strategy that might lead to improved activity

被引:43
作者
Bratsos, Ioannis
Serli, Barbara
Zangrando, Ennio
Katsaros, Nikos
Alessio, Enzo
机构
[1] Univ Trieste, Dipartimento Sci Chim, I-34127 Trieste, Italy
[2] NCSR Demokritos, Inst Chem Phys, GR-15310 Athens, Greece
关键词
D O I
10.1021/ic0613964
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
A series of new Ru(II)-DMSO complexes containing dicarboxylate ligands (dicarb), namely, oxalate (ox), malonate (mal), methylmalonate (mmal), dimethylmalonate (dmmal), and succinate (suc), have been synthesized and structurally characterized. These compounds were prepared from the known Ru(II)-Cl-DMSO anticancer complexes cis,fac-[RuCl2(DMSO-S)(3)(DMSO-O)] (1) and trans-[RuCl2(DMSO-S)(4)] (2) and from the chloride-free precursor fac-[Ru(DMSO-S)(3)(DMSO-O)(3)][CF3SO3](2) (3), with the aim of assessing how the nature of the anionic ligands influences the biological activity of these species. Basically, the investigated ligands can be divided into two groups. The reaction of either 1 or 2 with K-2(dicarb) (dicarb = ox, mal, mmal) yielded preferentially the mononuclear species [K]fac-[RuCl(DMSO-S)(3)(eta(2)-dicarb)] (dicarb = mal, 6; mmal, 9; ox, 14) that contains a chelating dicarboxylate unit and a residual chloride. Likewise, when 3 was used as a precursor, the neutral mononuclear species fac-[Ru(DMSO-O)(DMSO-S)(3)(eta(2)-dicarb)] (dicarb = mal, 7; mmal, 10; ox, 16), which contains a DMSO-O ligand in the place of Cl-, was obtained. On the contrary, K-2(suc) and K-2(dmmal) yielded preferentially the dinuclear species [fac-Ru(DMSO-S)(3)(H2O)(mu-dicarb)](2) (dicarb = dmmal, 11; suc, 13), with two bridging dicarboxylate moieties. The two water molecules in anti geometry have strong intramolecular H-bonding with the non-coordinated oxygen atoms of the carboxylate groups. The solid-state X-ray structural data showed that the preferential binding mode of the investigated dicarboxylates, either bridging (mu) or chelating (eta(2)), is dictated mainly by steric reasons. Oxalate, unlike the other dicarboxylates, has also the bridging bis-chelate (eta(4),mu) coordination mode available: this was found in the dinuclear species [{fac-RuCl(DMSO-S)(3)}(2)(eta(4),mu-ox)] (15) and [{fac-Ru(DMSO-O)(DMSO-S)(3)}(2)(eta(4),mu-ox)][CF3SO3](2) (17). We also isolated the unprecedented neutral metallacycle, [fac-Ru(DMSO-S)(3)(eta(3),mu-ox)](4) (18), in which each oxalate unit has one unbound oxygen atom. The new complexes were thoroughly characterized by 1-D (H-1 and C-13) and 2-D (H-H- COSY and HMQC) NMR spectroscopy in solution and by IR spectroscopy in the solid state. The molecular structures of 10 compounds, 6-11, 13, 15, 17, and 18, were determined by X-ray crystallography. The behavior of selected complexes in aqueous solution was investigated by H-1 NMR spectroscopy.
引用
收藏
页码:975 / 992
页数:18
相关论文
共 74 条
[1]   NOVEL DIASTEREOMERS WITH OPPOSITE CHIRALITY AT RUTHENIUM FORMED BY N7, ALPHA-PO4 CHELATION OF 5'-DGMP TO THE ANTIMETASTATIC AGENT TRANS-RUCL2(DMSO)4 - NMR AND CD EVIDENCE [J].
ALESSIO, E ;
XU, YH ;
CAUCI, S ;
MESTRONI, G ;
QUADRIFOGLIO, F ;
VIGLINO, P ;
MARZILLI, LG .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (18) :7068-7071
[2]   Synthesis and reactivity of Ru-, Os-, Rh-, and Ir-halide-sulfoxide complexes [J].
Alessio, E .
CHEMICAL REVIEWS, 2004, 104 (09) :4203-4242
[3]   Ruthenium antimetastatic agents [J].
Alessio, E ;
Mestroni, G ;
Bergamo, A ;
Sava, G .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535
[4]  
Alessio E, 2004, MET IONS BIOL SYST, V42, P323
[5]   CIS-DIHALOTETRAKIS(DIMETHYL SULFOXIDE)RUTHENIUM(II) AND TRANS-DIHALOTETRAKIS(DIMETHYL SULFOXIDE)RUTHENIUM(II) COMPLEXES (RUX2(DMSO)4, X = CL, BR) - SYNTHESIS, STRUCTURE, AND ANTITUMOR-ACTIVITY [J].
ALESSIO, E ;
MESTRONI, G ;
NARDIN, G ;
ATTIA, WM ;
CALLIGARIS, M ;
SAVA, G ;
ZORZET, S .
INORGANIC CHEMISTRY, 1988, 27 (23) :4099-4106
[6]  
Allardyce CS, 2001, PLATIN MET REV, V45, P62
[7]  
[Anonymous], 1999, TOP BIOL INORG CHEM
[8]  
[Anonymous], 1999, J. Appl. Crystallogr, DOI [DOI 10.1107/S0021889899006020, 10.1107/S0021889899006020]
[9]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[10]  
Ballester G, 2001, ANGEW CHEM INT EDIT, V40, P792, DOI 10.1002/1521-3773(20010216)40:4<792::AID-ANIE7920>3.3.CO